— Know what they know.
Not Investment Advice

AMED NASDAQ

Amedisys, Inc.
1W: +0.1% 1M: +3.6% 3M: +7.8% 1Y: +3.0% 3Y: -17.4% 5Y: -56.5%
$100.99
Last traded 2025-08-15 — delisted
NASDAQ · Healthcare · Medical - Care Facilities · $3.3B mcap · 32M float · 1.61% daily turnover · Short 34% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

WEAK EDGE
51.2 / 100
NoneWeakNarrowWide
Primary source: Intangible Assets  ·  ROIC: 5.3%  ·  5Y Avg: 10.1%
Cost Advantage
47
Intangibles
69
Switching Cost
46
Network Effect
37
Scale
50
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. AMED shows a Weak competitive edge (51.2/100) — limited structural advantages that may face competitive pressure. The primary source of advantage is Intangible Assets. ROIC of 5.3% suggests modest returns relative to capital deployed.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
Analyst Recommendations
Strong Buy: 0Buy: 8Hold: 18Sell: 2Strong Sell: 0
Rating Summary
ConsensusHold
Avg Target$—
Analysts0
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2024-03-25 RBC Capital Frank Morgan $199 $100 -99 +8.5% $92.16
2023-07-06 Jefferies Brian Tanquilut Initiated $91 — -0.5% $91.28
2023-01-05 Leerink Partners — $131 $85 -46 -1.2% $86.00
2022-11-11 Stephens — $185 $106 -79 +15.5% $91.78
2022-07-26 Truist Financial David MacDonald Initiated $150 — +17.0% $128.18
2022-07-03 Deutsche Bank Justin Bowers $230 $175 -55 +57.9% $110.82
2022-04-29 Credit Suisse — Initiated $182 — +38.8% $131.12
2022-04-29 Raymond James — Initiated $180 — +40.2% $128.41
2022-04-29 Leerink Partners — Initiated $131 — -0.7% $131.89
2022-02-24 BMO Capital Matthew Borsch Initiated $190 — +18.8% $159.90
2022-02-24 RBC Capital Ben Hendrix Initiated $199 — +24.5% $159.90
2022-02-23 Benchmark Co. Bill Sutherland Initiated $175 — +18.3% $147.93
2022-02-23 Deutsche Bank Justin Bowers Initiated $230 — +55.5% $147.93
2021-11-03 Stephens Scott Fidel Initiated $185 — +6.3% $174.01

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ 70 Grade A+
Profitability
50
Balance Sheet
71
Earnings Quality
79
Growth
61
Value
46
Momentum
88
Safety
100
Cash Flow
73
The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. AMED scores highest in Safety (100/100) and lowest in Value (46/100). An overall grade of A+ places AMED among the highest-quality companies in its peer group.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
4.04
Safe Zone
Piotroski F-Score
9/9
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Beneish M-Score
-3.03
Unlikely Manipulator
Ohlson O-Score
-8.28
Bankruptcy prob: 0.0%
Low Risk
Credit Rating
AA-
Score: 84.0/100
Trend: Improving
Earnings Quality
100/100
OCF/NI: 1.60x
Accruals: -4.1%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. AMED scores 4.04, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. AMED scores 9/9, signaling strong financial health across all three dimensions. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. AMED's score of -3.03 falls below this threshold, suggesting earnings are unlikely to be manipulated. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. AMED's implied 0.0% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. AMED receives an estimated rating of AA- (score: 84.0/100), with a improving trend. The Earnings Quality score measures how well reported earnings are backed by real cash. It evaluates the operating cash flow to net income ratio (OCF/NI ≥ 1.0 means every dollar of earnings is cash-backed) and the accruals ratio (the gap between earnings and cash flow relative to assets — lower is better). AMED's score of 100/100 is high — cash flows strongly support reported earnings.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
76.51x
PEG
2.33x
P/S
1.41x
P/B
2.91x
P/FCF
13.75x
P/OCF
13.50x
EV/EBITDA
20.32x
EV/Revenue
1.39x
EV/EBIT
20.10x
EV/FCF
14.24x
Earnings Yield
4.63%
FCF Yield
7.27%
Shareholder Yield
0.06%
Graham Number
$62.02
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. At 76.5x earnings, AMED is priced for high growth expectations. Graham's intrinsic value formula yields $62.02 per share, 63% below the current price.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
1.003
NI / EBT
×
Interest Burden
0.897
EBT / EBIT
×
EBIT Margin
0.069
EBIT / Rev
×
Asset Turnover
1.109
Rev / Assets
×
Equity Multiplier
1.838
Assets / Equity
=
ROE
12.7%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. AMED's ROE of 12.7% is driven by Asset Turnover (1.109), indicating efficient use of assets to generate revenue. A tax burden ratio of 1.00 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate
2.01%
Fair P/E
12.52x
Intrinsic Value
$57.03
Price/Value
1.73x
Margin of Safety
-72.51%
Premium
72.51%
Assessment
Neutral
Graham's classic formula uses analyst-projected growth to estimate a fair P/E (8.5 + 2g). Our adjusted version replaces that projection with AMED's realized 2.0% 3-year EPS CAGR, capped at 15% — demonstrated performance rather than forecasts, held to a rate companies have historically sustained. AMED trades at a 73% premium to its adjusted intrinsic value of $57.03, suggesting the market is pricing in future growth beyond what historical earnings support. The adjusted fair P/E of 12.5x compares to the current market P/E of 76.5x.

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$100.99
Median 1Y
$96.23
5th Pctile
$53.15
95th Pctile
$174.40
Ann. Volatility
37.8%
25th–75th percentile 5th–95th percentile Median path Historical
All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Current
ROE 24.5% 25.3% 27.5% 31.0% 26.5% 24.0% 21.8% 15.1% 12.6% 12.0% 11.0% 0.2% 0.3% 1.0% -0.0% 10.5% 11.7% 6.2% 10.0% 12.7% 12.70%
ROA 11.8% 13.0% 13.4% 15.2% 12.4% 12.2% 11.0% 7.8% 6.2% 6.2% 5.8% 0.1% 0.1% 0.5% -0.0% 5.5% 6.1% 3.2% 5.4% 6.9% 6.91%
ROIC 16.9% 18.6% 20.0% 21.1% 15.0% 13.2% 11.7% 9.7% 8.3% 8.6% 8.4% 0.3% 0.4% -3.0% -7.6% 8.5% 10.5% 7.2% 6.3% 5.3% 5.29%
ROCE 17.1% 19.9% 22.2% 27.0% 20.5% 19.5% 17.5% 13.0% 11.5% 11.3% 11.2% 4.9% 5.2% 4.5% 5.0% 12.2% 10.6% 7.7% 9.3% 9.6% 9.64%
Gross Margin 45.3% 44.3% 44.7% 45.3% 43.9% 43.3% 44.1% 43.3% 42.3% 43.6% 43.4% 46.2% 44.0% 75.4% 20.6% 22.1% 42.6% 42.4% 43.8% 79.0% 79.04%
Operating Margin 11.6% 11.3% 12.8% 13.8% 10.3% 8.6% 8.8% 8.5% 7.0% 8.2% 7.6% 6.8% 7.6% 6.0% 9.2% 10.8% 5.2% -3.3% 7.3% 7.3% 7.33%
Net Margin 13.2% 8.2% 9.3% 14.2% 8.1% 6.1% 5.8% 5.3% 4.6% 5.6% 4.5% -14.5% 4.7% 6.9% 2.5% 5.5% 7.1% -3.4% 10.3% 10.9% 10.87%
EBITDA Margin 15.4% 15.1% 14.5% 20.9% 12.0% 10.5% 10.3% 9.8% 8.1% 9.3% 8.6% -8.8% 9.4% 7.6% 10.2% 11.9% 4.4% 0.5% 15.0% 7.4% 7.44%
FCF Margin 14.5% 13.7% 15.7% 12.0% 11.0% 8.2% 8.0% 7.5% 4.1% 5.7% 4.6% 4.5% 4.7% 5.6% 4.0% 3.9% 8.8% 9.1% 9.2% 9.8% 9.78%
OCF Margin 14.8% 13.9% 15.9% 12.3% 11.3% 8.5% 8.3% 7.8% 4.4% 6.0% 5.0% 5.1% 5.3% 6.1% 4.6% 4.2% 9.1% 9.4% 9.5% 10.0% 9.97%
ROE 3Y Avg snapshot only 7.44%
ROE 5Y Avg snapshot only 12.97%
ROA 3Y Avg snapshot only 4.06%
ROIC 3Y Avg snapshot only 3.93%
ROIC Economic snapshot only 4.36%
Cash ROA snapshot only 10.81%
Cash ROIC snapshot only 17.78%
CROIC snapshot only 17.45%
NOPAT Margin snapshot only 2.97%
Pretax Margin snapshot only 6.21%
R&D / Revenue snapshot only 0.00%
SGA / Revenue snapshot only 24.86%
SBC / Revenue snapshot only 1.22%
Valuation
Metric Trend Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Current
P/E Ratio 47.34 53.11 43.58 32.68 22.28 25.41 29.58 24.49 26.10 22.96 21.40 1278.55 1158.01 303.55 -5638.86 27.08 25.07 43.83 26.90 21.59 76.508
P/S Ratio 3.89 4.71 4.15 3.68 2.22 2.40 2.54 1.55 1.42 1.23 1.07 1.34 1.38 1.40 1.35 1.32 1.38 1.26 1.30 1.35 1.414
P/B Ratio 10.40 12.05 11.15 9.24 5.42 5.71 5.84 3.49 3.11 2.59 2.22 2.96 2.95 2.93 2.79 2.70 2.79 2.62 2.56 2.62 2.912
P/FCF 26.77 34.38 26.52 30.55 20.27 29.17 31.85 20.71 34.69 21.60 23.31 29.59 29.17 25.14 33.53 34.29 15.70 13.84 14.03 13.75 13.752
P/OCF 26.37 33.75 26.08 29.81 19.65 28.13 30.76 19.86 32.36 20.43 21.70 26.14 26.04 22.81 29.03 31.53 15.11 13.40 13.70 13.50 13.499
EV/EBITDA 31.00 34.51 29.31 22.80 15.44 18.14 20.59 16.98 17.38 15.45 14.18 34.75 33.52 36.83 32.31 14.94 17.25 19.79 17.18 20.32 20.321
EV/Revenue 4.03 4.82 4.27 3.77 2.42 2.63 2.77 1.81 1.68 1.45 1.27 1.51 1.56 1.56 1.51 1.46 1.47 1.33 1.37 1.39 1.393
EV/EBIT 40.95 45.12 36.55 26.62 17.50 20.07 23.01 19.53 20.07 17.55 15.99 45.30 43.17 49.22 42.00 16.77 19.54 24.95 20.56 20.10 20.098
EV/FCF 27.77 35.18 27.30 31.28 22.02 31.93 34.71 24.15 41.04 25.55 27.60 33.47 33.09 28.03 37.52 37.88 16.79 14.57 14.80 14.24 14.238
Earnings Yield 2.1% 1.9% 2.3% 3.1% 4.5% 3.9% 3.4% 4.1% 3.8% 4.4% 4.7% 0.1% 0.1% 0.3% -0.0% 3.7% 4.0% 2.3% 3.7% 4.6% 4.63%
FCF Yield 3.7% 2.9% 3.8% 3.3% 4.9% 3.4% 3.1% 4.8% 2.9% 4.6% 4.3% 3.4% 3.4% 4.0% 3.0% 2.9% 6.4% 7.2% 7.1% 7.3% 7.27%
PEG Ratio snapshot only 2.329
EV/OCF snapshot only 13.975
EV/Gross Profit snapshot only 2.664
Acquirers Multiple snapshot only 33.581
Shareholder Yield snapshot only 0.06%
Graham Number snapshot only $62.02
Leverage & Solvency
Metric Trend Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Current
Current Ratio 0.94 0.79 0.83 0.87 0.95 0.95 1.03 0.92 1.06 1.09 1.15 0.92 1.00 1.05 1.09 1.16 1.19 1.23 1.29 1.36 1.356
Quick Ratio 0.94 0.77 0.80 0.84 0.95 0.95 1.03 0.92 1.06 1.09 1.15 0.92 1.00 1.05 1.09 1.16 1.19 1.23 1.29 1.36 1.356
Debt/Equity 0.53 0.38 0.43 0.32 0.60 0.59 0.60 0.60 0.59 0.51 0.45 0.48 0.47 0.46 0.44 0.42 0.41 0.41 0.38 0.37 0.366
Net Debt/Equity 0.39 0.28 0.33 0.22 0.47 0.54 0.53 0.58 0.57 0.47 0.41 0.39 0.40 0.34 0.33 0.28 0.19 0.14 0.14 0.09 0.093
Debt/Assets 0.25 0.20 0.21 0.18 0.28 0.29 0.30 0.30 0.30 0.27 0.25 0.25 0.24 0.24 0.23 0.22 0.22 0.22 0.21 0.20 0.204
Debt/EBITDA 1.54 1.06 1.09 0.78 1.59 1.70 1.93 2.53 2.77 2.58 2.45 5.02 4.72 5.14 4.58 2.12 2.36 2.91 2.40 2.74 2.741
Net Debt/EBITDA 1.11 0.78 0.84 0.53 1.23 1.57 1.70 2.41 2.69 2.39 2.20 4.04 3.97 3.81 3.43 1.41 1.12 0.99 0.89 0.69 0.693
Interest Coverage 16.97 20.03 25.05 34.30 33.47 30.42 25.17 12.06 9.67 8.26 6.69 2.89 2.80 2.27 2.54 6.19 5.47 4.08 5.43 6.03 6.035
Equity Multiplier 2.12 1.94 2.00 1.83 2.14 1.99 1.97 2.03 1.95 1.88 1.80 1.97 1.95 1.93 1.92 1.88 1.86 1.89 1.82 1.80 1.797
Cash Ratio snapshot only 0.691
Debt Service Coverage snapshot only 5.969
Cash to Debt snapshot only 0.747
FCF to Debt snapshot only 0.521
Defensive Interval snapshot only 179.5 days
Efficiency & Turnover
Metric Trend Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Current
Asset Turnover 1.44 1.46 1.41 1.35 1.25 1.29 1.28 1.23 1.13 1.16 1.16 1.12 1.11 1.11 1.12 1.12 1.11 1.12 1.11 1.11 1.109
Inventory Turnover 221.53 201.49 145.52 186.50 — 209.65 150.89 192.39 — — — — — — — — — — — — —
Receivables Turnover 8.00 8.41 7.78 8.33 8.40 8.35 7.81 7.59 7.70 7.78 7.60 7.63 7.16 7.33 6.89 7.20 7.48 7.71 6.99 7.36 7.364
Payables Turnover 31.34 32.07 34.19 34.55 30.31 30.49 32.88 31.14 28.92 30.76 33.16 30.51 31.00 29.59 31.56 41.93 41.77 46.83 45.47 40.65 40.647
DSO 46 43 47 44 43 44 47 48 47 47 48 48 51 50 53 51 49 47 52 50 49.6 days
DIO 2 2 3 2 0 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0.0 days
DPO 12 11 11 11 12 12 11 12 13 12 11 12 12 12 12 9 9 8 8 9 9.0 days
Cash Conversion Cycle 36 34 39 35 31 33 38 38 35 35 37 36 39 37 41 42 40 40 44 41 40.6 days
Fixed Asset Turnover snapshot only 19.236
Cash Velocity snapshot only 7.122
Capital Intensity snapshot only 0.922
Growth (YoY)
Metric Trend Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Current
Revenue 7.0% 5.9% 6.9% 11.4% 9.1% 6.9% 5.0% 0.9% 0.7% 0.4% 0.5% 0.6% 0.3% 0.6% 0.8% 2.7% 4.2% 5.0% 5.3% 4.9% 4.92%
Net Income 31.2% 44.8% 58.4% 92.7% 32.5% 13.9% -5.4% -43.2% -45.1% -43.3% -41.2% -98.3% -97.8% -91.3% -1.0% 47.1% 47.2% 5.6% 213.2% 33.6% 33.61%
EPS 30.2% 44.2% 58.6% 94.5% 34.0% 15.3% -4.1% -42.7% -44.6% -42.9% -41.0% -98.3% -97.8% -91.4% -1.0% 46.4% 46.7% 5.6% 211.7% 34.4% 34.41%
FCF 60.0% 46.1% 84.3% 3.4% -17.6% -35.8% -46.5% -37.3% -62.4% -30.8% -41.9% -39.3% 15.5% -1.3% -12.0% -12.1% 93.8% 72.5% 1.4% 1.7% 1.66%
EBITDA 21.3% 24.2% 31.1% 51.1% 31.2% 10.9% -3.2% -35.0% -37.7% -35.0% -32.9% -58.9% -51.7% -54.6% -47.5% 1.3% 91.0% 66.8% 79.4% -26.6% -26.57%
Op. Income 15.3% 23.6% 38.0% 49.5% 33.8% 14.9% -5.4% -26.4% -31.3% -28.2% -24.2% -17.5% -7.7% -13.5% -5.1% 16.5% 7.2% -18.7% -28.9% -48.3% -48.27%
OCF Growth snapshot only 1.49%
Asset Growth snapshot only 4.63%
Equity Growth snapshot only 9.54%
Debt Growth snapshot only -4.91%
Shares Change snapshot only -0.60%
Dividend Growth snapshot only -1.00%
Growth (CAGR)
Metric Trend Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Current
Revenue 3Y 10.6% 10.5% 10.7% 11.2% 10.5% 10.0% 8.7% 6.9% 5.5% 4.4% 4.1% 4.2% 3.3% 2.6% 2.1% 1.4% 1.7% 2.0% 2.2% 2.7% 2.73%
Revenue 5Y 10.2% 10.1% 9.8% 9.8% 9.4% 9.0% 8.8% 8.4% 8.2% 7.7% 7.4% 6.9% 6.4% 6.1% 5.4% 4.8% 4.2% 3.7% 3.7% 4.0% 4.03%
EPS 3Y 58.5% 83.5% 70.6% 53.2% 35.5% 20.5% 15.8% 4.5% -1.1% -1.7% -3.6% -73.5% -74.7% -61.6% — -23.2% -16.8% -31.2% -16.1% 2.0% 2.01%
EPS 5Y — — 39.7% 45.9% 40.6% 42.1% 33.9% 29.8% 24.2% 32.4% 22.9% -49.1% -50.4% -38.8% — -2.1% 0.1% -11.6% -2.1% 3.4% 3.41%
Net Income 3Y 56.8% 82.3% 68.3% 51.4% 35.7% 20.5% 15.6% 4.2% -1.5% -2.2% -4.1% -73.7% -74.8% -61.7% — -23.2% -16.6% -31.3% -15.7% 2.2% 2.18%
Net Income 5Y — — 39.5% 45.2% 39.8% 41.2% 32.8% 28.6% 22.9% 31.4% 21.5% -49.5% -50.4% -38.7% — -2.0% 0.1% -11.8% -2.1% 3.1% 3.14%
EBITDA 3Y 42.2% 40.6% 38.7% 32.3% 25.7% 21.3% 15.7% 5.2% -0.3% -3.6% -5.2% -26.1% -26.7% -31.1% -30.1% -14.8% -16.9% -21.0% -14.2% -11.3% -11.29%
EBITDA 5Y 72.5% 76.1% 31.0% 34.2% 32.5% 30.0% 24.1% 22.2% 18.6% 14.9% 11.6% -9.2% -9.8% -12.0% -11.4% 2.0% -1.8% -7.4% -4.3% -7.3% -7.26%
Gross Profit 3Y 10.9% 11.9% 12.9% 14.9% 14.0% 13.6% 11.9% 9.6% 7.5% 6.1% 5.6% 6.6% 5.2% 9.8% 4.4% -2.2% -1.9% -8.5% -3.0% 9.1% 9.08%
Gross Profit 5Y 9.5% 9.8% 10.0% 10.9% 10.5% 10.2% 9.9% 9.4% 9.1% 8.8% 8.6% 8.5% 8.3% 11.8% 8.4% 4.7% 3.8% -1.4% 1.8% 9.3% 9.25%
Op. Income 3Y 47.2% 40.8% 39.8% 27.3% 21.4% 17.5% 12.2% 6.6% 2.0% 0.6% -0.3% -3.2% -5.3% -10.7% -12.0% -10.9% -12.1% -20.4% -20.0% -20.8% -20.80%
Op. Income 5Y — — 32.4% 34.1% 34.5% 34.4% 26.5% 30.3% 24.0% 18.1% 14.4% 4.6% 2.6% 0.2% 0.3% 3.1% 1.0% -6.5% -7.8% -11.4% -11.37%
FCF 3Y 47.9% 44.0% 43.9% 27.2% 9.5% -5.7% -3.4% -6.7% -20.9% -13.4% -17.0% -26.7% -29.0% -24.0% -35.1% -30.6% -5.6% 5.6% 7.3% 12.3% 12.32%
FCF 5Y 32.4% 26.8% 33.0% 33.2% 45.8% 31.4% 22.7% 14.2% 0.0% 5.8% -1.5% -4.8% -10.6% -10.5% -14.4% -15.4% 2.1% 2.0% 4.0% -1.7% -1.68%
OCF 3Y 43.0% 39.8% 41.5% 26.7% 9.2% -5.5% -3.3% -6.5% -20.0% -12.9% -16.2% -24.3% -26.6% -22.0% -32.3% -29.2% -5.3% 5.5% 7.0% 11.4% 11.45%
OCF 5Y 26.4% 21.8% 26.1% 28.4% 36.0% 24.9% 18.9% 11.9% -0.9% 4.7% -1.4% -3.1% -9.3% -9.3% -12.4% -14.6% 2.1% 1.9% 3.6% -1.8% -1.83%
Assets 3Y 26.1% 24.4% 23.2% 28.5% 38.7% 37.3% 17.2% 18.4% 17.8% 16.1% 10.6% 6.4% 8.2% 9.5% 9.9% 9.8% 3.4% 4.8% 4.6% 3.5% 3.45%
Assets 5Y 19.2% 18.0% 17.4% 17.6% 21.8% 20.4% 20.3% 19.9% 19.9% 19.4% 18.2% 21.4% 22.8% 23.5% 12.0% 11.9% 12.0% 11.1% 8.7% 6.1% 6.13%
Equity 3Y 13.9% 16.2% 12.9% 28.9% 26.8% 24.6% 22.9% 20.6% 19.0% 18.0% 16.7% 11.8% 11.2% 9.6% 11.4% 8.8% 8.2% 6.8% 7.5% 7.7% 7.74%
Book Value 3Y 15.1% 17.0% 14.4% 30.5% 26.5% 24.6% 23.1% 20.9% 19.5% 18.6% 17.4% 12.6% 11.7% 10.0% 11.6% 8.7% 8.0% 6.9% 7.0% 7.6% 7.55%
Dividend 3Y 1.1% 18.5% 22.2% 18.0% 18.8% -31.2% -33.6% -32.6% -39.0% -92.2% — — — 2.0% — — — — — — —
Growth Quality
Metric Trend Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Current
Revenue Stability 0.98 0.97 0.98 0.98 0.98 0.98 0.99 0.97 0.96 0.93 0.92 0.88 0.86 0.84 0.83 0.81 0.85 0.89 0.90 0.95 0.951
Earnings Stability 0.97 0.93 0.86 0.86 0.96 0.93 0.89 0.60 0.52 0.44 0.33 0.01 0.08 0.18 0.25 0.14 0.19 0.44 0.31 0.09 0.088
Margin Stability 0.97 0.97 0.97 0.96 0.96 0.96 0.96 0.96 0.97 0.97 0.97 0.96 0.96 0.90 0.95 0.95 0.95 0.83 0.92 0.89 0.892
Rev. Growth Consistency 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
Earn. Growth Consistency 1.00 1.00 1.00 1.00 1.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 1.00 1.000
FCF Positive Streak 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Earnings Persistence 0.88 0.82 0.50 0.50 0.87 0.94 0.98 0.83 0.82 0.83 0.84 0.50 0.50 0.50 0.20 0.50 0.50 0.50 0.20 0.87 0.866
Earnings Smoothness 0.73 0.63 0.55 0.37 0.72 0.87 0.94 0.45 0.42 0.45 0.48 0.00 0.00 0.00 — 0.00 0.00 0.00 — 0.71 0.712
ROE Trend 0.02 0.00 0.04 0.08 0.03 0.01 -0.02 -0.09 -0.11 -0.11 -0.12 -0.21 -0.18 -0.16 -0.15 0.03 0.05 -0.00 0.04 0.07 0.071
Gross Margin Trend 0.01 0.02 0.03 0.04 0.03 0.02 0.02 0.01 0.00 -0.00 -0.01 -0.00 0.00 0.09 0.03 -0.03 -0.04 -0.16 -0.07 0.10 0.102
FCF Margin Trend 0.04 0.02 0.05 -0.00 -0.01 -0.04 -0.04 -0.05 -0.09 -0.05 -0.07 -0.05 -0.03 -0.01 -0.02 -0.02 0.04 0.04 0.05 0.06 0.056
Sustainable Growth Rate -5.6% -8.7% -8.6% -7.6% -7.8% -2.2% -2.0% -1.9% -1.4% 11.9% 11.0% 0.2% 0.3% -1.5% — 8.1% 9.3% 6.2% 10.0% 12.7% 12.70%
Internal Growth Rate — — — — — — — — — 6.5% 6.2% 0.1% 0.1% — — 4.4% 5.1% 3.3% 5.7% 7.4% 7.42%
Cash Flow Quality
Metric Trend Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Current
OCF/Net Income 1.80 1.57 1.67 1.10 1.13 0.90 0.96 1.23 0.81 1.12 0.99 48.92 44.47 13.31 -194.22 0.86 1.66 3.27 1.96 1.60 1.599
FCF/OCF 0.98 0.98 0.98 0.98 0.97 0.96 0.97 0.96 0.93 0.95 0.93 0.88 0.89 0.91 0.87 0.92 0.96 0.97 0.98 0.98 0.982
FCF/Net Income snapshot only 1.570
OCF/EBITDA snapshot only 1.454
CapEx/Revenue 0.2% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.6% 0.6% 0.6% 0.6% 0.3% 0.3% 0.3% 0.2% 0.2% 0.18%
CapEx/Depreciation snapshot only 0.152
Accruals Ratio -0.09 -0.07 -0.09 -0.01 -0.02 0.01 0.00 -0.02 0.01 -0.01 0.00 -0.06 -0.06 -0.06 -0.05 0.01 -0.04 -0.07 -0.05 -0.04 -0.041
Sloan Accruals snapshot only 0.032
Cash Flow Adequacy snapshot only 54.291
Earnings Quality Score snapshot only 1.000
Dividends & Buybacks
Metric Trend Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Current
Dividend Yield 50.5% 66.6% 74.3% 77.8% 1.4% 39.9% 33.8% 55.5% 47.6% 0.0% 0.0% 0.0% 0.0% 0.8% 0.8% 0.8% 0.8% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $119.29 $195.50 $196.62 $190.63 $203.35 $64.61 $58.18 $58.33 $46.09 $0.03 $0.00 $0.00 $0.00 $0.78 $0.78 $0.78 $0.78 $0.00 $0.00 $0.00 $0.00
Payout Ratio 23.9% 35.4% 32.4% 25.4% 30.4% 10.1% 10.0% 13.6% 12.4% 0.8% 0.0% 0.0% 0.0% 2.5% — 23.0% 20.2% 0.0% 0.0% 0.0% 0.00%
FCF Payout Ratio 13.5% 22.9% 19.7% 23.8% 27.6% 11.6% 10.8% 11.5% 16.5% 0.8% 0.0% 0.0% 0.0% 20.7% 28.4% 29.1% 12.6% 0.0% 0.0% 0.0% 0.00%
Total Payout Ratio 24.2% 35.7% 33.0% 26.0% 30.8% 10.7% 10.2% 14.0% 12.8% 22.2% 18.4% 2.3% 1.2% 3.0% — 29.4% 25.6% 9.1% 4.8% 1.3% 1.31%
Div. Increase Streak 0 1 1 1 1 0 0 0 0 0 — — — 0 0 0 0 — — — —
Chowder Number 8.27 1.30 1.49 1.36 2.05 -0.27 -0.37 -0.14 -0.30 -1.00 — — — 25.12 — — — — — — —
Buyback Yield 0.7% 0.6% 1.5% 1.6% 2.1% 2.2% 0.7% 1.7% 1.3% 0.9% 0.9% 0.2% 0.1% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.1% 0.06%
Net Buyback Yield 0.7% 0.6% 1.5% 1.6% 2.1% 2.2% 0.7% 1.7% 1.3% 0.9% 0.8% 0.2% 0.1% 0.1% 0.2% 0.2% 0.2% 0.2% 0.2% 0.1% 0.06%
Total Shareholder Return 51.1% 67.2% 75.7% 79.4% 1.4% 42.1% 34.5% 57.2% 48.9% 1.0% 0.8% 0.2% 0.1% 1.0% 1.0% 1.1% 1.0% 0.2% 0.2% 0.1% 0.06%
DuPont Factors
Metric Trend Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Current
Tax Burden (NI/EBT) 0.88 0.87 0.85 0.82 0.75 0.75 0.75 0.75 0.73 0.74 0.74 0.05 0.05 0.26 -0.02 0.78 0.95 0.79 0.76 1.00 1.003
Interest Burden (EBT/EBIT) 0.94 0.95 0.96 0.97 0.97 0.97 0.96 0.91 0.89 0.87 0.85 0.65 0.64 0.56 0.40 0.72 0.77 0.69 0.95 0.90 0.897
EBIT Margin 0.10 0.11 0.12 0.14 0.14 0.13 0.12 0.09 0.08 0.08 0.08 0.03 0.04 0.03 0.04 0.09 0.08 0.05 0.07 0.07 0.069
Asset Turnover 1.44 1.46 1.41 1.35 1.25 1.29 1.28 1.23 1.13 1.16 1.16 1.12 1.11 1.11 1.12 1.12 1.11 1.12 1.11 1.11 1.109
Equity Multiplier 2.07 1.95 2.05 2.03 2.13 1.97 1.98 1.94 2.04 1.93 1.88 2.00 1.95 1.91 1.86 1.92 1.90 1.91 1.87 1.84 1.838
Per Share
Metric Trend Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Current
EPS (Diluted TTM) $4.99 $5.52 $6.08 $7.49 $6.69 $6.37 $5.83 $4.29 $3.71 $3.64 $3.44 $0.07 $0.08 $0.31 $-0.02 $3.39 $3.85 $2.07 $3.44 $4.56 $4.56
Book Value/Share $22.74 $24.34 $23.75 $26.51 $27.52 $28.37 $29.50 $30.16 $31.14 $32.25 $33.06 $30.90 $31.67 $32.40 $33.00 $34.05 $34.64 $34.68 $36.11 $37.52 $36.06
Tangible Book/Share $-7.80 $-5.95 $-6.47 $-3.91 $-12.18 $-11.45 $-10.51 $-12.55 $-11.45 $-10.34 $-8.13 $-10.52 $-9.39 $-8.53 $-7.83 $-6.67 $-5.93 $-4.91 $-2.84 $-1.84 $-1.84
Revenue/Share $60.78 $62.31 $63.78 $66.59 $67.04 $67.46 $67.82 $67.81 $68.08 $68.19 $68.45 $68.43 $67.85 $67.95 $68.27 $69.28 $70.05 $71.77 $71.40 $73.13 $71.77
FCF/Share $8.83 $8.53 $9.99 $8.02 $7.35 $5.55 $5.41 $5.07 $2.79 $3.87 $3.15 $3.09 $3.20 $3.78 $2.75 $2.68 $6.15 $6.56 $6.60 $7.15 $6.55
OCF/Share $8.97 $8.69 $10.15 $8.22 $7.59 $5.75 $5.60 $5.29 $2.99 $4.09 $3.39 $3.50 $3.59 $4.17 $3.17 $2.91 $6.39 $6.78 $6.76 $7.29 $6.78
Cash/Share $3.39 $2.46 $2.33 $2.78 $3.78 $1.30 $2.07 $0.81 $0.55 $1.24 $1.51 $2.93 $2.38 $3.84 $3.66 $4.76 $7.41 $9.27 $8.58 $10.27 $9.27
EBITDA/Share $7.91 $8.69 $9.30 $11.00 $10.49 $9.77 $9.12 $7.22 $6.59 $6.39 $6.14 $2.98 $3.16 $2.88 $3.19 $6.79 $5.98 $4.83 $5.69 $5.01 $5.01
Debt/Share $12.15 $9.24 $10.10 $8.60 $16.64 $16.62 $17.57 $18.23 $18.27 $16.50 $15.04 $14.94 $14.93 $14.80 $14.61 $14.36 $14.11 $14.07 $13.63 $13.74 $13.74
Net Debt/Share $8.76 $6.78 $7.77 $5.82 $12.85 $15.32 $15.50 $17.41 $17.72 $15.26 $13.52 $12.01 $12.55 $10.96 $10.95 $9.60 $6.71 $4.80 $5.06 $3.47 $3.47
Academic Models
Metric Trend Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Current
Altman Z-Score — — — — — — — — — — — — — — — — — — — — 4.045
Altman Z-Prime snapshot only 5.923
Piotroski F-Score 6 6 8 8 6 5 4 5 4 7 5 7 5 5 3 5 7 8 8 9 9
Beneish M-Score -2.84 -2.67 -2.80 -2.50 -2.36 -2.27 -2.32 -2.36 -2.30 -2.43 -2.47 -2.89 -2.73 -2.95 -1.77 -1.61 -2.70 -2.43 -7.29 -3.03 -3.032
Ohlson O-Score snapshot only -8.276
Net-Net WC snapshot only $-8.47
EVA snapshot only $-63366147.98
Credit
Metric Trend Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Current
Credit Rating snapshot only AA-
Credit Score 91.32 93.83 93.69 95.27 87.59 87.69 87.14 78.95 77.49 76.02 73.00 58.85 60.24 61.76 61.26 71.84 77.43 73.49 77.38 83.99 83.988
Credit Grade snapshot only 4
Credit Trend snapshot only 12.151
Implied Spread (bps) snapshot only 100.000
Industry Credit Rank snapshot only 80
Sector Credit Rank snapshot only 80

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms